| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2153 |
| Trial ID | NCT04035434 |
| Disease | B-Cell Acute Lymphoblastic Leukemia | Non-Hodgkin's Lymphoma | B-Cell Malignancy |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CTX110 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) |
| Year | 2019 |
| Country | Australia|Canada|France|Germany|Spain|United States |
| Company sponsor | CRISPR Therapeutics AG |
| Other ID(s) | CRSP-ONC-001 |
| Cohort 1 | |||||||||||
|
|||||||||||